The global tangential flow filtration market is set for substantial growth, with a revenue estimation of $1.9 billion in 2023, and a projected expansion to $3.6 billion by 2028, showcasing a notable CAGR of 13.5% during this period. This comprehensive research delves into industry trends, pricing dynamics, patent analysis, key stakeholders, and market behavior. The market’s robust growth is attributed to increasing R&D investments in pharma-biotech companies and ongoing technological advancements in filtration technologies.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=72081607
Segment Analysis:
1. Systems Segment Leading the Way:
- In 2022, the systems segment commanded the largest market share within the tangential flow filtration market. This segment is poised to exhibit the highest CAGR from 2023 to 2028. Tangential filtration systems offer automated and mechanical filtration solutions, ensuring operational reliability. They offer benefits like high retention rates, energy efficiency, cost-effectiveness, and reduced cross-contamination risks. The systems segment is further categorized into single-use and reusable systems, with a growing preference for single-use technology in biopharmaceutical processes.
2. Microfiltration: A Leading Technique:
- In terms of technique, microfiltration led the tangential flow filtration market in 2022. Microfiltration encompasses various filter configurations and is versatile in removing suspended matter, microorganisms, and other contaminants. This technique finds applications in clarification, cell purification, biomass recovery, and the removal of organic matter in bioprocessing.
Key Market Players:
The global tangential flow filtration market is a highly consolidated space with several major players, including:
- Merck KGaA (Germany)
- Danaher Corporation (US)
- Sartorius AG (Germany)
- Parker Hannifin Corporation (US)
- Repligen Corporation (US)
- Alfa Laval Corporate AB (Sweden)
- Andritz (Austria)
- Meissner Filtration Products, Inc. (US)
- Antylia Scientific (US)
- Donaldson Company, Inc. (US)
- Koch Separation Solutions (US)
- Sterlitech Corporation (US)
- Synder Filtration, Inc (US)
- PendoTECH LLC (US)
- Microfilt India Pvt. Ltd. (India)
- BIONET (Spain)
- Sysbiotech GmbH (Austria)
- Hangzhou Cobetter Filtration Equipment (China)
- FORMULATRIX, Inc (US)
- Mantec Technical Ceramics (UK)
- Smartflow Technologies, Inc. (US)
- Tami Industries (France)
- SPF Technologies (US)
- NovaSep (France)
- ABEC, Inc. (US)
Company Highlights:
1. Danaher Corporation (US)
- Danaher is a key player in the market, boasting a robust portfolio of filtration products, including membranes and systems. The company has seen consistent revenue growth through strategic agreements, acquisitions, and expansions. Notable collaborations include General Electric Life Sciences (US) and Sartorius AG (Germany).
2. Merck KGaA (Germany)
- Merck KGaA is a leading force in the tangential flow filtration market, positioning itself as a premier technology and solutions provider. The company’s expansive portfolio and global presence make it a growth catalyst in the TFF market, particularly in the field of cell and gene therapy.
Request Free Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=72081607
OPPORTUNITY: Increasing demand for biologics
The demand for biologics has been increasing steadily over the years, driven by several factors, such as the growing prevalence of chronic diseases such as cancer, diabetes, and autoimmune disorders, an aging population, and advancements in biotechnology. The increasing demand for biologics is also reflected in the number of new biologic drugs approved by regulatory agencies. For instance, in 2022, the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) approved more than 30 new oncology agents and new indications for previously approved agents during Q4 2022. Most of these approvals were for new biologics or new indications, with more than 11 different biologics and biosimilars receiving at least one approval.
TFF is an essential step in the upstream and downstream processing of biologics. It separates and purifies the target biologic from other components in the cell culture, such as cell debris, DNA, and proteins. As the demand for biologics continues to grow, the need for TFF in the manufacturing process of these biologics is expected to increase, creating opportunities for market growth in the TFF market.
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
sales@marketsandmarkets.com
